{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:31:04Z","timestamp":1789205464783,"version":"build-2803163510"},"reference-count":40,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T00:00:00Z","timestamp":1479772800000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100007772","name":"Danone Research Centre for Specialised Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007772","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Diab\u00e8te et Risque Vasculaire"},{"DOI":"10.13039\/501100008966","name":"Soci\u00e9t\u00e9 Francophone du Diab\u00e8te","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Plasma copeptin, a surrogate for vasopressin, has been associated with a decline in renal function and albuminuria in population-based studies as well as with progression of diabetic nephropathy in people with type 2 diabetes. We assessed the risk of kidney and coronary events and all-cause mortality associated with plasma copeptin in people with type 1 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Plasma copeptin was measured in baseline samples of the GENEDIAB (n = 398; 56% male; mean \u00b1 SD age 45 \u00b1 12 years and diabetes duration 28 \u00b1 10 years) and GENESIS (n = 588; 52% male; age 42 \u00b1 11 years; diabetes duration 27 \u00b1 9 years) cohorts. Follow-up data were available for 218 GENEDIAB and 518 GENESIS participants. Median duration of follow-up was 10.2 and 5.0 years, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Upper sex-specific tertiles of copeptin were associated with a higher incidence of end-stage renal disease (ESRD) during follow-up (hazard ratio [HR] for third vs. first tertile 26.5 [95% CI 8.0\u2013163.3; P &amp;lt; 0.0001]; analysis in pooled cohorts adjusted for age, sex, duration of diabetes, and cohort membership). The highest tertile of copeptin was also associated with incidence of myocardial infarction or coronary revascularization (HR 2.2 [95% CI 1.2\u20134.0]; P = 0.01) and all-cause mortality (HR 3.3 [95% CI 1.8\u20136.5]; P &amp;lt; 0.0001) during follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Plasma copeptin is a predictor for the risk of ESRD, coronary heart disease, and all-cause mortality in people with type 1 diabetes. Results are consistent with data from experimental and epidemiological studies, suggesting that high circulating levels of vasopressin are deleterious to renal function.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-1003","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:58:47Z","timestamp":1476233927000},"page":"2288-2295","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":55,"title":["Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes"],"prefix":"10.2337","volume":"39","author":[{"given":"Gilberto","family":"Velho","sequence":"first","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"El Boustany","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lef\u00e8vre","sequence":"additional","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris, H\u00f4pitaux Universitaires Est Parisien\u2013Tenon, Service de Biochimie et Hormonologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Mohammedi","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bichat, DHU FIRE, D\u00e9partment de Diab\u00e9tologie, Endocrinologie et Nutrition, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Fumeron","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, UFR de M\u00e9decine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Potier","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bichat, DHU FIRE, D\u00e9partment de Diab\u00e9tologie, Endocrinologie et Nutrition, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, UFR de M\u00e9decine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Bankir","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Sorbonne Universit\u00e9s, Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Bouby","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Sorbonne Universit\u00e9s, Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[{"name":"D\u00e9partment de Endocrinologie et Diab\u00e9tologie, CHU de Poitiers, Poitiers, France"},{"name":"INSERM, Unit\u00e9 de Recherche 1082, Poitiers, France"},{"name":"INSERM, CIC 1402, Poitiers, France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine et Pharmacie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bichat, DHU FIRE, D\u00e9partment de Diab\u00e9tologie, Endocrinologie et Nutrition, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, UFR de M\u00e9decine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Roussel","sequence":"additional","affiliation":[{"name":"INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bichat, DHU FIRE, D\u00e9partment de Diab\u00e9tologie, Endocrinologie et Nutrition, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, UFR de M\u00e9decine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"key":"2022031221064422800_B1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000045879","article-title":"Vasopressin and diabetes mellitus","volume":"87","author":"Bankir","year":"2001","journal-title":"Nephron"},{"key":"2022031221064422800_B2","first-page":"E317","article-title":"Regulation of plasma vasopressin in insulin-dependent diabetes mellitus","volume":"249","author":"Zerbe","year":"1985","journal-title":"Am J Physiol"},{"key":"2022031221064422800_B3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00125-015-3496-9","article-title":"Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats","volume":"58","author":"Taveau","year":"2015","journal-title":"Diabetologia"},{"key":"2022031221064422800_B4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrneph.2013.22","article-title":"Vasopressin: a novel target for the prevention and retardation of kidney disease","volume":"9","author":"Bankir","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2022031221064422800_B5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ki.2013.23","article-title":"The medicinal use of water in renal disease","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"key":"2022031221064422800_B6","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","article-title":"Non-peptide arginine-vasopressin antagonists: the vaptans","volume":"371","author":"Decaux","year":"2008","journal-title":"Lancet"},{"key":"2022031221064422800_B7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1210\/jc.2010-2499","article-title":"Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states","volume":"96","author":"Balanescu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221064422800_B8","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1210\/jc.2014-2295","article-title":"Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease","volume":"99","author":"Roussel","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221064422800_B9","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1210\/jc.2008-2278","article-title":"Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome","volume":"94","author":"Saleem","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221064422800_B10","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1161\/CIRCULATIONAHA.109.909663","article-title":"Plasma copeptin and the risk of diabetes mellitus","volume":"121","author":"Enh\u00f6rning","year":"2010","journal-title":"Circulation"},{"key":"2022031221064422800_B11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00125-012-2545-x","article-title":"Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study","volume":"55","author":"Abbasi","year":"2012","journal-title":"Diabetologia"},{"key":"2022031221064422800_B12","doi-asserted-by":"crossref","DOI":"10.1038\/ijo.2012.88","article-title":"Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malm\u00f6 Diet and Cancer Study cardiovascular cohort","author":"Enhorning","year":"2013","journal-title":"Int J Obes"},{"key":"2022031221064422800_B13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00592-014-0609-8","article-title":"Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study","volume":"52","author":"Then","year":"2015","journal-title":"Acta Diabetol"},{"key":"2022031221064422800_B14","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1210\/jc.2016-1113","article-title":"Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community","volume":"101","author":"Roussel","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221064422800_B15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1681\/ASN.2014030260","article-title":"Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study","volume":"26","author":"Ponte","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022031221064422800_B16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000439061","article-title":"Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study","volume":"42","author":"Roussel","year":"2015","journal-title":"Am J Nephrol"},{"key":"2022031221064422800_B17","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jdiacomp.2015.07.006","article-title":"Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register","volume":"29","author":"Pikkemaat","year":"2015","journal-title":"J Diabetes Complications"},{"key":"2022031221064422800_B18","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.2337\/dc13-0683","article-title":"Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria","volume":"36","author":"Velho","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031221064422800_B19","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1172\/JCI119321","article-title":"Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group","volume":"99","author":"Marre","year":"1997","journal-title":"J Clin Invest"},{"key":"2022031221064422800_B20","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.2337\/diacare.27.11.2661","article-title":"Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study","volume":"27","author":"Hadjadj","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031221064422800_B21","first-page":"575","article-title":"The lesions and natural history of diabetic retinopathy","volume-title":"Textbook of Diabetes","author":"Kohner","year":"1991"},{"key":"2022031221064422800_B22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2015.04.002","article-title":"Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes","volume":"86","author":"Patente","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"2022031221064422800_B23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1186\/s12933-014-0163-2","article-title":"Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes","volume":"14","author":"Mohammedi","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2022031221064422800_B24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1210\/jc.2008-1426","article-title":"Copeptin in the differential diagnosis of hyponatremia","volume":"94","author":"Fenske","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221064422800_B25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.2009.397","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort","volume":"77","author":"Meijer","year":"2010","journal-title":"Kidney Int"},{"key":"2022031221064422800_B26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2022031221064422800_B27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jdiacomp.2016.04.012","article-title":"Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes","volume":"30","author":"Bjornstad","year":"2016","journal-title":"J Diabetes Complications"},{"key":"2022031221064422800_B28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease","volume":"6","author":"Meijer","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031221064422800_B29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2022031221064422800_B30","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031221064422800_B31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/TP.0b013e3181b11ae4","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients","volume":"88","author":"Meijer","year":"2009","journal-title":"Transplantation"},{"key":"2022031221064422800_B32"},{"key":"2022031221064422800_B33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/heartjnl-2015-308183","article-title":"Copeptin predicts coronary artery disease cardiovascular and total mortality","volume":"102","author":"Tasevska","year":"2016","journal-title":"Heart"},{"key":"2022031221064422800_B34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1681\/ASN.2010070691","article-title":"Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus","volume":"22","author":"Fenske","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022031221064422800_B35","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","article-title":"Vasopressin V1a and V1b receptors: from molecules to physiological systems","volume":"92","author":"Koshimizu","year":"2012","journal-title":"Physiol Rev"},{"key":"2022031221064422800_B36","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1053\/meta.2002.34052","article-title":"Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas","volume":"51","author":"Abu-Basha","year":"2002","journal-title":"Metabolism"},{"key":"2022031221064422800_B37","first-page":"F973","article-title":"Effect of water intake on the progression of chronic renal failure in the 5\/6 nephrectomized rat","volume":"258","author":"Bouby","year":"1990","journal-title":"Am J Physiol"},{"key":"2022031221064422800_B38","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0024-3205(99)00330-6","article-title":"Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats","volume":"65","author":"Bouby","year":"1999","journal-title":"Life Sci"},{"key":"2022031221064422800_B39","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","article-title":"The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes","volume":"58","author":"Groop","year":"2009","journal-title":"Diabetes"},{"key":"2022031221064422800_B40","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc16-1003","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/12\/2288\/544586\/dc161003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/12\/2288\/544586\/dc161003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:10:44Z","timestamp":1647126644000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/12\/2288\/31462\/Plasma-Copeptin-Kidney-Outcomes-Ischemic-Heart"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,10,11]]},"published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-1003","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]}}}